US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

13.31

+0.34002.62%

Post-market: 13.310.00000.00%19:30 EDT

Volume:580.67K

Turnover:7.75M

Market Cap:617.29M

PE:-2.63

High:13.93

Open:12.99

Low:12.32

Close:12.97

52wk High:40.43

52wk Low:9.10

Shares:46.38M

Float Shares:13.40M

Volume Ratio:0.92

T/O Rate:4.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.77

PE(LYR):-0.72

Loading ...

Overview Company News Filings

MapLight Therapeutics price target raised to $52 from $48 at UBS

MapLight Therapeutics initiated with an Outperform at BMO Capital

Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares

Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares

Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout

Maplight Therapeutics Director Martin Babler Files Initial Beneficial Ownership Statement

Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating

MT Newswires Live

Maplight Therapeutics Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $46

THOMSON REUTERS

Maplight Therapeutics Initiated at Strong Buy by Raymond James

MapLight Shareholders Back Board Slate and Auditor

Maplight Therapeutics Shareholders Elect Three Directors at Annual Meeting

Maplight Therapeutics Names Martin Babler, Troy Cox to Board of Directors

Maplight Therapeutics Announces Changes to Board of Directors

THOMSON REUTERS

Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)

Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained

MapLight Therapeutics Is Maintained at Buy by Needham

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)

BUZZ-Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss

MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit

MapLight says Phase 2 IRIS trial of ML-004 in autism misses primary endpoint

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/MPLT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":13.31,"timestamp":1788292800000,"preClose":12.97,"halted":0,"volume":580665,"hourTrading":{"tag":"盘后","latestPrice":13.31,"preClose":13.31,"latestTime":"19:30 EDT","volume":6288,"amount":83684.01,"timestamp":1788305405977,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.026214340786430212,"floatShares":13402700,"shares":46377800,"eps":-5.058,"marketStatus":"Closed","change":0.34,"latestTime":"09-01 16:00:00 EDT","open":12.99,"high":13.93,"low":12.32,"amount":7753043.144655,"amplitude":0.124133,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":5,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":12.97,"preHourTrading":{"tag":"盘前","latestPrice":12.64,"preClose":12.97,"latestTime":"09:06 EDT","volume":467,"amount":6081.369735,"timestamp":1788268008957,"change":-0.33,"changeRate":-0.025443,"amplitude":0.048574},"postHourTrading":{"tag":"盘后","latestPrice":13.31,"preClose":13.31,"latestTime":"19:30 EDT","volume":6288,"amount":83684.01,"timestamp":1788305405977,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.915644,"impliedVol":0.9901,"impliedVolPercentile":0.2576},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":13402700,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":0.915644,"shares":46377800,"dividePrice":0,"high":13.93,"amplitude":0.124133,"preClose":12.97,"low":12.32,"week52Low":9.1,"pbRate":"1.77","week52High":40.43,"institutionHeld":0,"latestPrice":13.31,"eps":-5.058,"divideRate":0,"volume":580665,"delay":0,"ttmEps":-5.058,"open":12.99,"prevYearClose":17.565,"prevWeekClose":12.6,"prevMonthClose":12.97,"prevQuarterClose":35.84,"fiveDayClose":12.54,"twentyDayClose":12.94,"sixtyDayClose":28.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-08-31","current":-2.631475,"percent":0.9,"low":-9.047313,"twenty":-8.059278,"median":-7.418032,"eighty":-6.321753,"high":-2.251599,"avg":-6.888801,"sd":1.701235,"marketCap":700254059},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-08-31","current":-3.046875,"twenty":-8.059278,"median":-7.418032,"eighty":-6.321753,"marketCap":700254059}],"updateTime":1788301774933},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653527435","title":"MapLight Therapeutics price target raised to $52 from $48 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653527435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653527435?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:11","pubTimestamp":1784632310,"startTime":"0","endTime":"0","summary":"UBS raised the firm’s price target on MapLight Therapeutics (MPLT) to $52 from $48 and keeps a Buy rating on the shares. The upcoming Phase 2 reado...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-52-from-48-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-52-from-48-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653468092","title":"MapLight Therapeutics initiated with an Outperform at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2653468092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653468092?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:30","pubTimestamp":1784579421,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $46 price target Published first on TheFly – the ultim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-an-outperform-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-an-outperform-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMO","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294732","title":"Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294732","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652294732?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:03","pubTimestamp":1784541805,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common sharesMapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 36,284 shares of Voting Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLbXNwwm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652236527","title":"Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2652236527","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652236527?lang=en_us&edition=fundamental","pubTime":"2026-07-18 09:44","pubTimestamp":1784339040,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common sharesMaplight Therapeutics Chief Medical Officer Erin Pennock Foff reported sales totaling 57,303 shares on July 15-17.Sha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260718:nNDL49Yb9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648689162","title":"Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2648689162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648689162?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:15","pubTimestamp":1783005317,"startTime":"0","endTime":"0","summary":"Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on MapLight Therapeutics, Inc., retaining the price target of $45.00. Francoi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-maplight-therapeutics-reaffirms-45-price-target-ahead-of-key-phase-2-zephyr-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-maplight-therapeutics-reaffirms-45-price-target-ahead-of-key-phase-2-zephyr-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646890463","title":"Maplight Therapeutics Director Martin Babler Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646890463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646890463?lang=en_us&edition=fundamental","pubTime":"2026-06-26 05:47","pubTimestamp":1782424064,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics director Martin Babler files initial beneficial ownership statementMapLight Therapeutics director Martin Babler filed an initial Form 3 statement dated June 23.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL3Ksnj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646877598","title":"Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2646877598","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646877598?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:36","pubTimestamp":1782387416,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $39.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPLT","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646787219","title":"Maplight Therapeutics Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $46","url":"https://stock-news.laohu8.com/highlight/detail?id=2646787219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646787219?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:18","pubTimestamp":1782386337,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42X0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879758","title":"Maplight Therapeutics Initiated at Strong Buy by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646879758?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:05","pubTimestamp":1782381900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings(END) Dow Jones NewswiresJune 25, 2026 06:05 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","LU1363072403.SGD","IE00BGHQF748.EUR","BK4585","BK4139","LU2265009873.SGD","IE00B3QW5Z07.USD","LENZ","BK4539","RJF","MPLT","LU0971096721.USD","BK4127","BK4007","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645189085","title":"MapLight Shareholders Back Board Slate and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2645189085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645189085?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:28","pubTimestamp":1782300504,"startTime":"0","endTime":"0","summary":"An announcement from MapLight Therapeutics, Inc. ( ($MPLT) ) is now available. On June 23, 2026, MapLight Therapeutics stockholders held their 2026...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maplight-shareholders-back-board-slate-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maplight-shareholders-back-board-slate-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897327","title":"Maplight Therapeutics Shareholders Elect Three Directors at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897327?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:15","pubTimestamp":1782299741,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics shareholders elect three directors at annual meetingMaplight Therapeutics held its annual stockholder meeting on June 23, 2026.Stockholders backed the selection of RSM US LLP as ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDLTxGJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645089221","title":"Maplight Therapeutics Names Martin Babler, Troy Cox to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645089221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645089221?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:01","pubTimestamp":1782298911,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics names Martin Babler, Troy Cox to board of directorsMapLight Therapeutics added Martin Babler and Troy Cox to its board following their election at the June 23 annual meeting.Babl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL4dzdNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014021.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4139","LU2095319765.USD","SG9999014013.SGD","NDAQ","BK4585","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","ALMS","IE00B64PRP62.GBP","BK4007","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645892144","title":"Maplight Therapeutics Announces Changes to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645892144","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645892144?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:00","pubTimestamp":1782298801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7ZV0DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839227","title":"Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839227?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:55","pubTimestamp":1782219353,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum maintained a Buy rating on MapLight Therapeutics, Inc., with a price target of $40.00. Vog...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835890","title":"Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835890?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:28","pubTimestamp":1782214104,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman reiterated a Buy rating on MapLight Therapeutics, Inc. yesterday and set a price target of $34.00. Sean Laaman h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/overweight-rating-reaffirmed-on-ml004s-irritability-efficacy-and-safety-profile-34-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/overweight-rating-reaffirmed-on-ml004s-irritability-efficacy-and-safety-profile-34-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645716200","title":"MapLight Therapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2645716200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645716200?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:36","pubTimestamp":1782149760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 13:36 ET (17:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645607190","title":"Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645607190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645607190?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:20","pubTimestamp":1782148814,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and MapLight Therapeutics, Inc. (MPLT)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbvie-abbv-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-abbvie-abbv-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310800379.SGD","BK4585","LU1244550577.SGD","BK4559","LU1291159041.SGD","LU0708994859.HKD","LU1093756168.USD","IE0002141913.USD","LU1244550494.USD","LU0203345920.USD","LU0965509101.SGD","LU0234570918.USD","LU0098860793.USD","LU1023059063.AUD","LU0417517546.SGD","LU1989772840.SGD","LU0432979614.USD","LU0965508806.USD","LU2089283258.USD","LU0820561909.HKD","LU2347655156.SGD","LU0256863811.USD","SG9999001440.SGD","LU0965509010.AUD","IE000BZT7R73.USD","LU1057294990.SGD","LU0057025933.USD","IE00BBT3K403.USD","LU0553294199.USD","LU1929549753.HKD","LU0256863902.USD","LU1037948541.HKD","BK4534","LU0795875169.SGD","LU1718418525.SGD","LU2089284900.SGD","LU0234572021.USD","LU0511384066.AUD","BK4533","LU2129689605.HKD","LU1732800096.USD","LU1983299246.USD","LU1585245621.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","LU0912757837.SGD","ABBV","LU2237443382.USD","BK4550","LU1496350171.SGD","LU0943347566.SGD","LU2087621335.USD","LU0868494617.USD","SG9999015952.SGD","LU0122379950.USD","LU2023251221.USD","BK4139","IE000WAW04H5.SGD","LU0861579265.USD","IE00B19Z3581.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU2237443465.HKD","LU0289739343.SGD","LU1934455277.USD","SG9999011175.SGD","LU0211328371.USD","MPLT","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00BLSP4239.USD","LU2237443978.SGD","LU1093756325.SGD","LU0029864427.USD","IE00BGHQF631.EUR","LU0203347892.USD","LU2237443549.SGD","LU0795875086.SGD","LU1244550221.USD","LU0058720904.USD","IE0004445239.USD","LU1074936037.SGD","LU0211327993.USD","LU2129689431.USD","SG9999015978.USD","IE00B4R5TH58.HKD","IE0002270589.USD","LU0965509283.SGD","LU0868494708.USD","LU1003077747.HKD","LU0545039389.USD","IE00BDGV0183.EUR","LU0128525929.USD","IE00BJJMRZ35.SGD","LU0320765646.SGD","LU0310799852.SGD","SG9999015945.SGD","LU0689472784.USD","LU0198837287.USD","LU0289739699.SGD","LU0456855351.SGD","LU0949170772.SGD","LU0882574055.USD","LU2357627491.SGD","LU2237443895.HKD","LU1496350502.SGD","LU0942090050.USD","LU1839511570.USD","LU0985320562.USD","LU1670627923.USD","LU1061106388.HKD","LU1267930573.SGD","LU1037948897.HKD","LU1934455863.HKD","LU1989772923.USD","LU0689626769.HKD","IE00BLSP4452.SGD","LU0820561818.USD","IE000SO60NU8.SGD","LU2089984988.USD","LU2129689514.USD","LU2237443622.USD","IE00B3PB1722.GBP","IE00B42XCP33.USD","LU0124676726.USD","LU1162221912.USD","LU1670628061.USD","LU2468319806.SGD","LU2133065610.SGD","LU0823416689.USD","LU1732799900.SGD","LU1934455194.USD","IE000F7OJYX1.SGD","LU0158827948.USD","LU0859254822.USD","SG9999015986.USD","IE0000B7K699.USD","LU0069063385.USD","LU0661504455.SGD","BK4566","LU0170899867.USD","LU1551013425.SGD","LU0738911758.USD","IE000MB6IJN5.SGD","LU0472753341.HKD","LU1430594728.SGD","LU0289961442.SGD","LU1551013342.USD","LU1989771016.USD","LU2112291526.USD","IE00BVYPNV92.GBP","IE00BN8TJ469.HKD","IE0009355771.USD","LU1267930490.SGD","IE00BVYPNW00.USD","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645730230","title":"BUZZ-Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2645730230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645730230?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:53","pubTimestamp":1782140005,"startTime":"0","endTime":"0","summary":"BUZZ-Maplight Therapeutics rises as autism drug shows benefit in subset despite trial miss** Shares of Maplight Therapeutics MPLT.O rise 6.8% to $30.79** Co says its autism drug, ML-004, did not improve social communication after 12 weeks, missing its main goal in a mid-stage trial ** \"We'd argue this indication had low Street expectations prior to the readout,\" Jefferies analyst Andrew Tsai said** However, in a pre-specified analysis of small group of adolescents with moderate to severe irritability, the drug produced a large reduction in irritability symptoms compared to placebo, with an effect size of 1.33 described as \"clinically meaningful\"** \"While the primary endpoint missed, ML-004 showed a clinically meaningful signal in irritability among adolescents with moderate or greater baseline irritability, a setting with an established regulatory path and meaningful unmet need,\" TD Cowen analyst Joseph Thome says** Co plans to meet U.S. FDA to discuss next steps for development focuse","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645162024","title":"MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2645162024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645162024?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:59","pubTimestamp":1782129540,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents.The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial.The company noted that an approved pharmacologic therapy for social communication currently doesn't exist.However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options.MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645934029","title":"MapLight says Phase 2 IRIS trial of ML-004 in autism misses primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2645934029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645934029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126058,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics reported topline Phase 2 IRIS results for ML-004 in autism spectrum disorder; findings were presented with the announcement.The trial missed its primary goal on social communication, raising uncertainty for the program’s initial development thesis.A prespecified adolescent subgroup with higher baseline irritability showed meaningful improvement versus placebo, supporting a potential pivot toward that symptom domain.ML-004 was generally well tolerated, with no severe or serious adverse events reported in the active-treatment arm.Maplight plans an FDA End-of-Phase 2 meeting to determine next steps; Phase 2 ZEPHYR topline data for ML-007C-MA in schizophrenia is due by mid-August 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6C1V5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014039.USD","BK4585","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU0314104364.USD","BK4139","IE00BN0W2W23.USD","IE00B64PRP62.GBP","MPLT","BK4588","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":123,"code":"91000000","status":"200"}]}}